Screener
Vaxcyte, Inc. PCVX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders' Equity | ||
| Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 144,314,981 and 131,058,858 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 147 | 134 |
| Additional paid-in capital | 5,478,270 | 4,838,736 |
| Accumulated other comprehensive loss | (6,834) | 1,587 |
| Accumulated deficit | (2,475,569) | (2,154,947) |
| Total stockholders' equity | 2,996,014 | 2,685,510 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s common stock?
- Vaxcyte, Inc. (PCVX) reported common stock of 500M in Q1 2026.
- How has Vaxcyte, Inc.'s common stock changed year-over-year?
- Vaxcyte, Inc.'s common stock decreased by 0.0% year-over-year, from 500M to 500M.
- What is the long-term trend for Vaxcyte, Inc.'s common stock?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s common stock has grown at a 521.3% compound annual growth rate (CAGR), from 54K to 500M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Vaxcyte, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude